Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan in symptomatic diastolic heart failure
NCT00171106Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2002
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in Heart failure with preserved ejection fraction (HFpEF) comparing Valsartan with Placebo (2 arms). Primary endpoint: Change in baseline exercise test at 14 weeks. Started Dec 2002; status: completed.
02
Drugs
valsartan
03
Conditions
Heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00171106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171106.